Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Barry S Coller

Showing results (101-110 of 120) with videos related to

Pageof 12
Sort By:
Journal of the American Heart Association|August 27, 2020
First Human Use of RUC-4: A Nonactivating Second-Generation Small-Molecule Platelet Glycoprotein IIb/IIIa (Integrin αIIbβ3) Inhibitor Designed for Subcutaneous Point-of-Care Treatment of ST-Segment-Elevation Myocardial InfarctionDean J Kereiakes, Tim D Henry, Anthony N DeMaria, et al.
Human Mutation|February 8, 2006
Molecular diversity of Glanzmann thrombasthenia in southern India: new insights into mRNA splicing and structure-function correlations of alphaIIbbeta3 integrin (ITGA2B, ITGB3)Hava Peretz, Nurit Rosenberg, Meytal Landau, et al.
American Heart Journal|June 16, 2026
The Effect of Zalunfiban on High Sensitivity Cardiac Troponin and the Association with Clinical Outcomes in Patients with STEMIJames L Januzzi, C Michael Gibson, Gerald Chi, et al.
Journal of Clinical and Translational Science|February 20, 2018
The Rockefeller University Clinical Scholars (KL2) Program 2006-2016Sarah J Schlesinger, Michelle Romanick, Jonathan N Tobin, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|May 25, 2021
Pharmacokinetics, pharmacodynamics, and tolerability of subcutaneous administration of a novel glycoprotein IIb/IIIa inhibitor, RUC-4, in patients with ST-segment elevation myocardial infarctionWillem L Bor, Kai L Zheng, Anne H Tavenier, et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems|December 2, 2025
Mass balance and metabolite profiling of <sup>14</sup>C-Zalunfiban in humans following single-dose subcutaneous administrationRobert B MacArthur, Sem A O F Rikken, Spandana R Vootukuri, et al.
Science Translational Medicine|March 17, 2012
Structure-guided design of a high-affinity platelet integrin αIIbβ3 receptor antagonist that disrupts Mg²⁺ binding to the MIDASJieqing Zhu, Won-Seok Choi, Joshua G McCoy, et al.
Progress in Community Health Partnerships : Research, Education, and Action|February 24, 2017
From the Bench to the Barbershop: Community Engagement to Raise Awareness About Community-Acquired Methicillin-Resistant <i>Staphylococcus aureus</i> and Hepatitis C Virus InfectionAndrea Leinberger-Jabari, Rhonda G Kost, Brianna D'Orazio, et al.
Journal of Clinical and Translational Science|May 30, 2023
Building an infrastructure to support the development, conduct, and reporting of informative clinical studies: The Rockefeller University experienceRhonda G Kost, Rita K Devine, Mark Fernands, et al.
American Heart Journal|April 23, 2023
Prepercutaneous coronary intervention Zalunfiban dose-response relationship to target vessel blood flow at initial angiogram in st-elevation myocardial infarction - A post hoc analysis of the cel-02 phase IIa studySem A O F Rikken, Willem L Bor, Abi Selvarajah, et al.
Pageof 12

Showing results (101-110 of 120) with videos related to

Sort By:
Pageof 12
Journal of the American Heart Association|August 27, 2020
First Human Use of RUC-4: A Nonactivating Second-Generation Small-Molecule Platelet Glycoprotein IIb/IIIa (Integrin αIIbβ3) Inhibitor Designed for Subcutaneous Point-of-Care Treatment of ST-Segment-Elevation Myocardial InfarctionDean J Kereiakes, Tim D Henry, Anthony N DeMaria, et al.
Human Mutation|February 8, 2006
Molecular diversity of Glanzmann thrombasthenia in southern India: new insights into mRNA splicing and structure-function correlations of alphaIIbbeta3 integrin (ITGA2B, ITGB3)Hava Peretz, Nurit Rosenberg, Meytal Landau, et al.
American Heart Journal|June 16, 2026
The Effect of Zalunfiban on High Sensitivity Cardiac Troponin and the Association with Clinical Outcomes in Patients with STEMIJames L Januzzi, C Michael Gibson, Gerald Chi, et al.
Journal of Clinical and Translational Science|February 20, 2018
The Rockefeller University Clinical Scholars (KL2) Program 2006-2016Sarah J Schlesinger, Michelle Romanick, Jonathan N Tobin, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|May 25, 2021
Pharmacokinetics, pharmacodynamics, and tolerability of subcutaneous administration of a novel glycoprotein IIb/IIIa inhibitor, RUC-4, in patients with ST-segment elevation myocardial infarctionWillem L Bor, Kai L Zheng, Anne H Tavenier, et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems|December 2, 2025
Mass balance and metabolite profiling of <sup>14</sup>C-Zalunfiban in humans following single-dose subcutaneous administrationRobert B MacArthur, Sem A O F Rikken, Spandana R Vootukuri, et al.
Science Translational Medicine|March 17, 2012
Structure-guided design of a high-affinity platelet integrin αIIbβ3 receptor antagonist that disrupts Mg²⁺ binding to the MIDASJieqing Zhu, Won-Seok Choi, Joshua G McCoy, et al.
Progress in Community Health Partnerships : Research, Education, and Action|February 24, 2017
From the Bench to the Barbershop: Community Engagement to Raise Awareness About Community-Acquired Methicillin-Resistant <i>Staphylococcus aureus</i> and Hepatitis C Virus InfectionAndrea Leinberger-Jabari, Rhonda G Kost, Brianna D'Orazio, et al.
Journal of Clinical and Translational Science|May 30, 2023
Building an infrastructure to support the development, conduct, and reporting of informative clinical studies: The Rockefeller University experienceRhonda G Kost, Rita K Devine, Mark Fernands, et al.
American Heart Journal|April 23, 2023
Prepercutaneous coronary intervention Zalunfiban dose-response relationship to target vessel blood flow at initial angiogram in st-elevation myocardial infarction - A post hoc analysis of the cel-02 phase IIa studySem A O F Rikken, Willem L Bor, Abi Selvarajah, et al.
Pageof 12